Nitroimidazoles and imaging hypoxia

[1]  W. Rumsey,et al.  Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  K. Fukuchi,et al.  Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  A. Maseri,et al.  Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. , 1994, The New England journal of medicine.

[4]  B. Dardzinski,et al.  Rapid tissue oxygen tension mapping using 19F inversion‐recovery echo‐planar imaging of P erfluoro‐15 ‐crown‐5‐ether , 1994, Magnetic resonance in medicine.

[5]  H. Hu,et al.  Ischemic penumbra in acute stroke: Demonstration by PET with fluorine-18 fluoromisonidazole , 1994 .

[6]  A. Nunn,et al.  TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. , 1994, Journal of medicinal chemistry.

[7]  L. Opie.  The mechanism of myocyte death in ischaemia. , 1993, European heart journal.

[8]  A. Nunn,et al.  Imaging Ischemic Tissue at Risk of Infarction during Stroke , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  A. Nunn,et al.  Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: new technetium compounds designed for imaging hypoxic tissue. , 1993, Bioconjugate chemistry.

[10]  W. Rumsey,et al.  A novel [99m]technetium-labeled nitroheterocycle capable of identification of hypoxia in heart. , 1993, Biochemical and biophysical research communications.

[11]  K. Krohn,et al.  Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  M. Parliament,et al.  Imaging tumor hypoxia and tumor perfusion. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  J. Gore,et al.  Imaging oxygen tension in liver and spleen by 19F NMR , 1993, Magnetic resonance in medicine.

[14]  D. Nowotnik,et al.  Syntheses of Some Nitroimidazole Substituted Boronic Acids: Precursors to Technetium‐99m Complexes with Potential for Imaging Hypoxic Tissue. , 1993 .

[15]  R. Moore,et al.  Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. D. Chapman,et al.  Radioiodinated 1-(2-fluoro-4-iodo-2,4-dideoxy-beta-L-xylopyranosyl)-2-nitroimidazole: a novel probe for the noninvasive assessment of tumor hypoxia. , 1992, Radiation research.

[17]  D. Nowotnik,et al.  Syntheses of some nitroimidazole substituted boronic acids: Precursors to technetium-99m complexes with potential for imaging hypoxic tissue , 1992 .

[18]  P. Antich,et al.  A noninvasive assessment of myocardial oxygen tension: 19f nmr spectroscopy of sequestered perfluorocarbon emulsion , 1992, Magnetic resonance in medicine.

[19]  L. Golberg,et al.  Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.

[20]  J. Rasey,et al.  Reduction of fluoromisonidazole, a new imaging agent for hypoxia. , 1991, Biochemical Pharmacology.

[21]  P. Allen,et al.  Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors. , 1991, Journal of the National Cancer Institute.

[22]  J. D. Chapman,et al.  Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  K. Krohn,et al.  Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging. , 1991, Journal of medicinal chemistry.

[24]  G. Wilson,et al.  Fluorescent markers for hypoxic cells: a study of nitroaromatic compounds, with fluorescent heterocyclic side chains, that undergo bioreductive binding. , 1991, Journal of medicinal chemistry.

[25]  I. Silver,et al.  Oxygen in mammalian tissue: methods of measurement and affinities of various reactions. , 1991, The American journal of physiology.

[26]  G. Wilson,et al.  Fluorescent markers for hypoxic cells. A study of novel heterocyclic compounds that undergo bio-reductive binding. , 1991, Biochemical pharmacology.

[27]  P. van der Meer,et al.  Xanthine oxidoreductase activity in perfused hearts of various species, including humans. , 1990, Circulation research.

[28]  R. A. Goldstein.  Wanted: dead or alive--the search for markers of myocardial viability. , 1990, Journal of the American College of Cardiology.

[29]  G. Brooks,et al.  Defining hypoxia: a systems view of VO2, glycolysis, energetics, and intracellular PO2. , 1990, Journal of applied physiology.

[30]  K. Krohn,et al.  Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.

[31]  J. Bolton,et al.  Kinetics and mechanism of the decomposition in aqueous solutions of 2-(hydroxyamino)imidazoles , 1989 .

[32]  J. Griffiths,et al.  Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. , 1989, International journal of radiation oncology, biology, physics.

[33]  J. Brown,et al.  Keynote address: hypoxic cell radiosensitizers: where next? , 1989, International journal of radiation oncology, biology, physics.

[34]  P. Olive,et al.  Misonidazole binding in SCCVII tumors in relation to the tumor blood supply. , 1989, International journal of radiation oncology, biology, physics.

[35]  C. Mathis,et al.  A radiosynthesis of fluorine-18 fluoromisonidazole. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  C. Dence,et al.  Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  M. Cerqueira,et al.  Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  R. Gatenby,et al.  Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. , 1988, International journal of radiation oncology, biology, physics.

[39]  W. Rumsey,et al.  The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration. , 1988, The Journal of biological chemistry.

[40]  R B Buxton,et al.  Evaluation of the 11CO2 Positron Emission Tomographic Method for Measuring Brain pH. I. pH Changes Measured in States of Altered PCO2 , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  K. Krohn,et al.  Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. , 1987, Radiation research.

[42]  E. Hall,et al.  Oxygen dependence for chemosensitization by misonidazole. , 1986, British Journal of Cancer.

[43]  C. Koch,et al.  Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. , 1986, International journal of radiation oncology, biology, physics.

[44]  P. Allen,et al.  Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T. , 1986, International journal of radiation oncology, biology, physics.

[45]  L. Wiebe,et al.  Iodoazomycin riboside (1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. Synthesis and in vitro characterization. , 1986, Radiation research.

[46]  A. J. Varghese,et al.  Properties of 2-hydroxylaminoimidazoles and their implications for the biological effects of 2-nitroimidazoles. , 1985, Chemico-biological interactions.

[47]  R. Okada,et al.  The persistent defect on exercise thallium imaging and its fate after myocardial revascularization: does it represent scar or ischemia? , 1985, American heart journal.

[48]  C. Patlak,et al.  Regional measurements of [14C]misonidazole distribution and blood flow in subcutaneous RT-9 experimental tumors. , 1985, Cancer research.

[49]  L. Wiebe,et al.  Electron-Affillic Compounds for Labelling Hypoxie Cells : The Synthesis and Characterization of 1-[2-(2-Iodophenoxy)-Ethyl]-2-Nitroimidazole , 1984, Nuklearmedizin.

[50]  B. Garrecht,et al.  The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. , 1983, The British journal of radiology.

[51]  W D Heiss,et al.  Flow thresholds of functional and morphological damage of brain tissue. , 1983, Stroke.

[52]  E. Clarke,et al.  Nitroimidazoles as anaerobic electron acceptors for xanthine oxidase. , 1982, Biochemical pharmacology.

[53]  K. Krohn,et al.  Bromomisonidazole: synthesis and characterization of a new radiosensitizer. , 1982, Radiation research.

[54]  A. Rauth,et al.  The metabolism and pharmacokinetics of the hypoxic cell radiosensitizer and cytotoxic agent, misonidazole, in C3H mice. , 1981, Radiation research.

[55]  B. Palcic,et al.  Reduction of misonidazole and its derivatives by xanthine oxidase. , 1981, Biochemical pharmacology.

[56]  J. D. Chapman,et al.  A marker for hypoxic cells in tumours with potential clinical applicability. , 1981, British Journal of Cancer.

[57]  J. Brown,et al.  The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole. , 1980, Radiation research.

[58]  E. Clarke,et al.  Anaerobic reduction of nitroimidazoles by reduced flavin mononucleotide and by xanthine oxidase. , 1980, Biochemical pharmacology.

[59]  G. T. Krishnamurthy,et al.  Labeled Metronidazoles as Potential New Agents for Amebic Hepatic Abscess Imaging , 1975, Nuklearmedizin.

[60]  L. Sapirstein,et al.  Regional blood flow by fractional distribution of indicators. , 1958, The American journal of physiology.

[61]  J. Brown,et al.  Structure-pharmacokinetic relationships for misonidazole analogues in mice , 2004, Cancer Chemotherapy and Pharmacology.

[62]  P Vaupel,et al.  Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. , 1994, Advances in experimental medicine and biology.

[63]  A. Nunn,et al.  Potential of nitroimidazoles as markers of hypoxia in heart. , 1994, Advances in experimental medicine and biology.

[64]  W. Rumsey,et al.  Detecting hypoxia in heart using phosphorescence quenching and 99mtechnetium-nitroimidazoles. , 1994, Advances in experimental medicine and biology.

[65]  D I Edwards,et al.  Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. , 1993, The Journal of antimicrobial chemotherapy.

[66]  L. Wiebe,et al.  Radioiodinated azomycin pyranoside (IAZP): a novel non-invasive marker for the assessment of tumor hypoxia. , 1992, Journal of nuclear biology and medicine.

[67]  Y. Shibamoto,et al.  Pharmacokinetics of fluorinated 2-nitroimidazole hypoxic cell radiosensitizers in murine peripheral nervous tissue. , 1992, International journal of radiation biology.

[68]  L. Kwock,et al.  Evaluation of a fluorinated 2-nitroimidazole binding to hypoxic cells in tumor-bearing rats by 19F magnetic resonance spectroscopy and immunohistochemistry. , 1992, Radiation research.

[69]  G. L. Kedderis,et al.  The metabolic activation of nitroheterocyclic therapeutic agents. , 1988, Drug metabolism reviews.

[70]  John M. Hoffman,et al.  Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. , 1987, Stroke.

[71]  K. Krohn,et al.  Synthesis and characterization of congeners of misonidazole for imaging hypoxia. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[72]  M J Welch,et al.  Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[73]  P. Jerabek,et al.  Synthesis of a fluorine-18 labeled hypoxic cell sensitizer , 1984 .

[74]  J. D. Chapman,et al.  Synthesis and in vivo studies of the radiosensitizer 4-[82Br]bromomisonidazole. , 1983, International journal of nuclear medicine and biology.

[75]  B. Holman,et al.  Acute myocardial infarct scintigraphy with infarct-avid radiotracers. , 1980, The Medical clinics of North America.

[76]  E. Clarke,et al.  Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. , 1979, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[77]  Dr Kifah,et al.  Cellular injury and adaptation Chapter two , 2022 .